In a global DNA methylation analysis of treatment-naïve bladder cancer patients, the DNA methylation in the GSTM2 and GSTM3 promoter was found to be higher in invasive tumors than in non-invasive types [34]. Here, GSTM2 is linked to urinary bladder carcinoma.